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Abstract
Protein-based subunit smallpox vaccines have shown their potential as effective alternatives to live virus vaccines in animal
model challenge studies. We vaccinated mice with combinations of three different vaccinia virus (VACV) proteins (A33, B5,
L1) and examined how the combined antibody responses to these proteins cooperate to effectively neutralize the
extracellular virus (EV) infectious form of VACV. Antibodies against these targets were generated in the presence or absence
of CpG adjuvant so that Th1-biased antibody responses could be compared to Th2-biased responses to the proteins with
aluminum hydroxide alone, specifically with interest in looking at the ability of anti-B5 and anti-A33 polyclonal antibodies
(pAb) to utilize complement-mediated neutralization in vitro. We found that neutralization of EV by anti-A33 or anti-B5 pAb
can be enhanced in the presence of complement if Th1-biased antibody (IgG2a) is generated. Mechanistic differences found
for complement-mediated neutralization showed that anti-A33 antibodies likely result in virolysis, while anti-B5 antibodies
with complement can neutralize by opsonization (coating). In vivo studies found that mice lacking the C3 protein of
complement were less protected than wild-type mice after passive transfer of anti-B5 pAb or vaccination with B5. Passive
transfer of anti-B5 pAb or monoclonal antibody into mice lacking Fc receptors (FcRs) found that FcRs were also important in
mediating protection. These results demonstrate that both complement and FcRs are important effector mechanisms for
antibody-mediated protection from VACV challenge in mice.
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Introduction
In the 1970s, the World Health Organization led a successful
campaign to eradicate smallpox using live vaccinia virus (VACV)
vaccines [1]. However, recent concern over the intentional or
accidental release of variola virus has led some of the world’s
nations to stockpile live VACV vaccines [2–4]. With the risk of
variola virus release minimal, concerns regarding live VACV
vaccine’s rare but serious side effects and many contraindications
[5–7] have led to the pursuit of safer smallpox vaccine strategies
[8–10]. Modified vaccinia virus Ankara (MVA), a highly atten-
uated VACV-derived vaccine, has been under development and
will likely soon become a safer alternative [11,12]. However, sub-
unit vaccination is an approach that does not rely on production of
a virus. We evaluated the efficacy and mechanism by which a
protein-based subunit vaccine can protect against orthopoxvirus
infection.
After vaccination, protection from orthopoxvirus disease heavily
depends on antibody responses in animal models [13–15] and
humans [16,17]. Many of the responses are directed against viral
surface proteins on the two virion forms, mature virus (MV) and
extracellular virus (EV). The MV form is the most abundant virion
form in infected cells [18] and is believed to mediate spread
between hosts. The EV form mediates dissemination within an
infected host [19–22]. The MV form contains a large set of surface
proteins, while the EV form contains an extra membrane and an
additional, unique subset of surface proteins. Antibody against
certain proteins of either form can be partially protective, such
as L1 on MV [23–27] and B5 or A33 on EV [15,23,26,28–30],
though optimal protection is seen when antibodies are directed
against both forms [23–26,31,32]. Subunit protein vaccination
including target antigens from both forms achieves protection
from lethal orthopoxvirus challenge in mouse and non-human
primate challenge models [23,32–35]. In theory, antibody gen-
erated against the MV form would act to neutralize a portion of
the initial infectious dose and antibody against the EV form could
then prevent some spread of progeny virus within a host. Having
these antibody responses present at the time of challenge could
then allow the host time to generate additional immune responses
and provide protection from lethal disease.
Serum from vaccinated animals or humans is capable of ef-
ficiently neutralizing the MV form of VACV [23,32,34,36,37];
however, direct antibody neutralization of the EV form has been
suboptimal at even high concentrations of anti-EV antibody [15,
29,38–41]. Therefore, understanding the mechanism by which
anti-EV antibodies provide protection has been of interest. Recent
mouse studies have elucidated that an IgG2a isotype monoclonal
antibody (mAb) against the B5 protein called B126 can neutralize
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20597EV in the presence of complement (C’) and utilizes C’ to partially
mediate protection in vivo [42,43]. This evidence suggests that
antibody against EV would be more effective if it was of an isotype
that mediated effector functions such as activation of C’ and/or Fc
receptor (FcR) dependent activity (e.g. antibody dependent cellular
cytotoxicity (ADCC)). Previous studies of antibody responses to
protein vaccination found that formulations that included
adjuvants that produced higher titers of IgG2a antibody in mice
and IgG1 antibody in non-human primates were more effective at
mediating protection than vaccines formulated without these
adjuvants [33,34]. This suggests that antibody with specific Fc
activities might be beneficial for protection.
By utilizing a high PFU luciferase reporter EV neutralization
assay, we find that polyclonal antibody responses against the EV
proteins A33 and B5 utilize C’ to neutralize virus in vitro, though
in mechanistically different ways. These findings shed light on how
differing viral proteins dictate the requirements for the host to
neutralize incoming virus with C’. Additionally, we show that
antibody against B5 utilizes C’ and FcRs to protect mice from
lethal VACV challenge. These findings add to our understanding
of how antibody can protect against orthopoxvirus disease and
highlights the importance of understanding antibody effector
functions necessary for protection to aid in the rational design of
anti-viral vaccines and therapeutic antibodies.
Materials and Methods
Proteins and vaccine formulations
Proteins used in the vaccine formulations were purified
recombinant baculovirus-expressed proteins that were previously
described [34] . Protein vaccines were prepared and used as
described previously [32]. Briefly, proteins (each at 2 mg/mouse)
and adjuvant(s) were prepared in sterile PBS and a final volume of
50 mL was injected intramuscularly into the hind leg of ketamine/
xylazine-anesthetized mice. For vaccines adjuvanted with alum
only (Alhydrogel, Accurate Chemical, Westbury, NY), formula-
tions included the alum at 200 mg aluminum ion/mouse. For
vaccines formulated with alum and CpG, the alum was at 100 mg
aluminum ion/mouse and the phosphorothioate B class mouse
specific CpG ODN 1826 (sequence 59-TCC ATG ACG TTC
CTG ACG TT-39; Coley Pharmaceutical Group, now Pfizer Inc.)
was used at 50 mg/mouse. On the day of vaccinations, vaccine
formulations were prepared, mixed at room temperature for 2–
3 hours, and loaded into 0.3 mL insulin syringes with a 29-gauge
needle (Becton Dickinson).
Mice, immunizations, and challenge
BALB/c mice and C57BL/6 mice were purchased from
Charles River and Jackson Laboratory, respectively. Fc-receptor
knockout mice (FcRKO) mice on the BALB/c background were
purchased from Taconic Farms. Complement component C3
knockout mice (C3KO) on the C57BL/6 background (originally
provided by J. D. Lambris, University of Pennsylvania) were bred
at the University of Pennsylvania. Active immunizations were
performed as previously described [32]. Briefly, mice were primed
by intramuscular vaccination, boosted 2 weeks later, and bled 1
day prior to challenge (approximately 3 weeks after the boost) to
assess successful antibody production and isotype analysis. In some
instances, additional mice were terminally bled prior to challenge
for serum to be used in in vitro EV neutralization assays. Passive
immunizations were performed using the anti-B5 rabbit polyclonal
antibody (pAb) R182 [26] (2 mg of purified total rabbit IgG /
mouse) or the anti-B5 monoclonal antibody (mAb) B126 [43]
(100 mg of purified mouse IgG /mouse; generously provided by
Kyowa Hakko Kirin Co. and S. Crotty, La Jolla Institute for
Allergy and Immunology). Antibodies, diluted in sterile saline at a
final volume of 300 mL/mouse for R182 or 100 mL/mouse for
B126, were injected intraperitoneally (i.p.) one day prior to
challenge. Control mice were given sterile saline only. Vaccinated
mice were challenged as described previously [32]. Briefly, VACV
(strain WR) was grown in BSC-1 cells (ATCCH Number CCL-
26
TM) and virus from cell lysates isolated by ultracentrifugation
through two sequential 36% sucrose cushions. Three weeks after
the boost protein vaccination or one day after passive immuni-
zation with antibody, mice were anaesthetized with ketamine/
xylazine and challenged intranasally with a lethal dose of VACV
in a total volume of 20 mL (10 mL/nostril) in sterile PBS.
Challenge doses were confirmed by titering on BSC-1 cells the
day of challenge and indicated in the figure legends. Mice were
weighed and monitored each day and mice that reached .30%
starting weight or met end point criteria were humanely
euthanized. Experiments were performed under a protocol that
was approved by the University of Pennsylvania Institutional
Animal Care and Use Committee (IACUC), Animal Welfare
Assurance number A3079-01. To minimize pain, all viral chal-
lenges and intramuscular vaccinations were performed under
ketamine/xylazine anesthesia. To minimize suffering after viral
challenge, mice were monitored and humanely euthanized when
end point criteria were met.
Antibody ELISA
Antibody ELISA was performed as previously described [32,
34]. Briefly, plates were coated overnight at 4uC with 0.5 mg/mL
non-his tagged recombinant A33, B5, or L1 protein in bicar-
bonate/carbonate coating buffer. After blocking with 5% non-fat
dry milk in PBS, 2-fold serial dilutions of mouse sera were
added and incubated for 1.5 hrs at 37uC. After washing, HRP-
conjugated rabbit anti-mouse IgG (Abcam, Cambridge, MA)
secondary antibody was added at 1:4000 in blocking buffer and
incubated at 37uC for 1 hr. Color development was performed
using ABTS substrate (Sigma) for 20 minutes at room tempera-
ture. The reaction was stopped using 1% SDS in distilled water.
IgG isotype was assessed similarly, using HRP-conjugated rat anti-
mouse IgG1 or IgG2a (BD Biosciences Pharmingen), or HRP-
conjugated goat anti-mouse IgG2c (SouthernBiotech, Birming-
ham, AL) secondary antibody diluted 1:1000, 1:1000, and 1:4000
respectively in blocking buffer and incubated for 1 hr at 37uC.
In vivo complement depletion
C’ was transiently depleted using native Cobra Venom Factor
(CVF) from Naja naja kaouthia (Quidel Corporation) as previously
described [43]. Briefly, 10 mg( ,4 units) of CVF in sterile saline
(100 mL total volume) was administered i.p to mice on days 21, 2,
and 5 of challenge. Complement depletion was confirmed on days
0, 3, and 6 by C3 western blotting [44], C3 ELISA [43], and
CH50 assay [45,46] (Fig. S1). We found that C’ was fully depleted
on days 0 and 3, but C’ activity and C3 protein were at ,50% the
levels of undepleted sera on day 6 confirming previous findings of
transient depletion [43]. Intranasal challenge was performed on
day 0.
EV production
RK-13 cells (ATCCH Number CCL-37
TM) were plated in 6-
well plates 2 days prior to use and used at 100% confluency. To
produce EV, RK-13 cells were infected with vaccinia IHD-JvFire
[47] (generously provided by B. Moss, NIH) in serum-free MEM
at MOI of 0.5. Two days after infection, supernatant was
harvested, clarified by centrifugation at 4506 ga t4 uC, and the
Antibody to Vaccinia EV, Complement, Fc Receptors
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presence of MV neutralizing monoclonal antibody 2D5 (1:500
dilution of ascites fluid) [48] . In general, based on titering of
supernatants in the presence or absence of 2D5, .80% of virus in
the supernatants was EV. Clarified media was stored on ice at 4uC
and used within a week of isolation. For EV expressing specific
human complement regulators, the same protocol for EV pre-
paration and titering was followed except that simian virus 40-
transformed aortic rat endothelial cells (SVAREC) stably trans-
fected with plasmids expressing human CD55 or human CD59
were used [49,50] (a generous gift of G. L. Smith, Imperial College
of London). We confirmed expression of human CD55 and hu-
man CD59 in these cell lines by western blotting using polyclonal
rabbit anti-human CD55 and anti-human CD59 antibodies (Santa
Cruz Biotechnology) (Fig. S2). The parental and stably transfected
SVAREC cells were maintained in DMEM with 10% FBS and
100 mg/mL hygromycin B.
EV neutralization in the presence of complement
Serum from vaccinated mice or rabbit pAb or mAb was serially
diluted 1:3 in triplicate in serum free MEM in a round-bottom 96-
well plate. Serum free MEM was added to all wells so that each
well had 50 mL total volume. Next, ,5610
4 PFU of EV
containing a 1:500 final dilution of anti-MV mAb 2D5 in MEM
was added to each well (22 mL/well) so that each well had a total
volume of 72 mL. Baby rabbit complement (C’) (Cedarlane
Laboratories, Burlington, NC) at a final dilution of 10% (8 mL)
was added to each well so that the final volume in each well was
80 mL. Alternatively, heat inactivated baby rabbit C’ (iC’) was
added as a negative control. The 96-well plates containing virus,
antibody, and C’ were incubated at 37uC for 30 minutes after
which the contents from each well was transferred to Costar 96-
well white clear-bottom tissue culture treated plates (Corning)
containing a monolayer of BSC-1 cells. The BSC-1 cells were pre-
pared on these plates 48 hours before use and subsequently used at
100% confluency. Once infected, the plates were incubated at
37uC for ,20 hours. Luciferase production was measured by
adding 100 mL of SuperLight
TM Luciferase Reporter Gene Assay
Reagent (BioAssay Systems, Hayward, Ca) directly to each well
and relative light unit (RLU) measurements obtained on a MLX
Revelation microtiter plate luminometer (Dynex Technologies).
To relate RLU readings to PFU, known amounts of EV were
serially diluted on the same BSC-1 plate to generate a standard
curve. Linear fit was calculated and RLU readings were converted
to PFU.
Neutralization of EV with human C’ (Sigma-Aldrich, St. Louis,
MO) or human C’ depleted of C1q (Complement Technology,
Tyler, TX) or C5 (Sigma-Aldrich, St. Louis, MO) was performed
using the same luciferase assay as above with the following
modifications. Prior to the addition of C’, virus and antibody were
incubated for 1 hour. After the addition of human C’ (used at a
concentration of 20%), the plate was incubated for an additional
1 hr. These changes were made because we found that neu-
tralization using human C’ with the rabbit and mouse antibodies
was less efficient than with baby rabbit C’. Percent neutralization
was calculated by dividing luciferase RLU readings from wells
containing antibody by RLU readings of control wells containing
no antibody for each serially diluted antibody. Percent neutrali-
zation by virolysis was calculated by the following formula: 100 –
[(%NAb – %NAb with C5defC’)/(%NAb – %NAb with hC’)*100]
where %NAb is percent neutralization with antibody, C5defC’ is
C5 deficient human C’ and hC’ is complete human C’. This
formula controls for any neutralization with antibody alone and
determines the contribution of the lytic pathway.
Statistics
Statistical significance was determined using Prism 5.0 software.
Differences in percent neutralization and weight loss were
calculated using an unpaired 2-tailed t-test. Differences in survival
were calculated using Kaplan-Meier analysis and log-rank test. P
values of less than 0.05 were considered significant.
Results
Protection from lethalVACV challenge requires the inclusion
of CpG adjuvant and correlates with the induction of IgG2a
antibody
We have previously shown that vaccinating mice and non-
human primates with a combination of VACV proteins and CpG
and aluminum hydroxide (alum) protects from a lethal poxvirus
infection [32,34]. Using different adjuvant systems (MPL+TDM
or QS21), Fogg et al. showed that vaccination with combinations
of proteins provided better protection than individual proteins
[23]. Here, we investigated the protection of BALB/c mice
vaccinated with both combination and individual proteins with
adjuvants CpG/alum or alum alone (Table 1). Mice that received
a vaccine adjuvanted only with alum succumbed to infection,
regardless of the combination of proteins given. Mice receiving
protein(s) with CpG/alum were able to survive infection to varying
degrees, with combination proteins achieving 100 percent survival.
The combination protein vaccines achieved 100 percent protec-
tion due to antibody generated against both MV and EV. L1/
CpG/alum and B5/CpG/alum showed partial protection.
Notably, while A33/CpG/alum showed no survival at this
challenge dose, the addition of A33 to L1/CpG/alum resulted
in less post-challenge weight loss than mice vaccinated with only
L1/CpG/alum (2% vs. 23% weight loss; p=0.0003) again de-
monstrating that combinations of proteins provided better pro-
tection than individual proteins.
Others have previously shown that the addition of CpG adju-
vant biases the immune response towards Th1 in mice [33,51–54].
As expected, IgG2a antibody was only produced in BALB/c mice
given the CpG/alum combination adjuvant (Fig. 1). IgG1 was
produced in both CpG/alum and alum only groups, with varying
titers to the individual proteins.
Sera from mice vaccinated with A33 or B5 /CpG/alum can
neutralize large numbers of EV particles in the presence
of complement
Given the correlation seen between the appearance of Th1-
biased antibodies (IgG2a in mice) and protection, as well as
previous studies showing that Th1-biased antibodies are more
protective than Th2-biased antibodies and can neutralize EV in
the presence of C’ [33,34,42,43], we next determined if sera from
vaccinated mice could neutralize EV in the presence of C’.
Previously, plaque reduction assays with small numbers of EV
(,50–150 PFU) were used to show neutralization; however, we
wished to test the ability of antibody and C’ to neutralize large
numbers of EV particles that are more likely present during an
infection. To do this, we developed an EV neutralization assay
with a recombinant VACV that expressed a luciferase reporter
protein. For this assay we generated standard curves with known
amounts of EV, which allowed for conversion of RLU to PFU. In
this assay, anti-L1 mAb 2D5 [48] was always added to neutralize
contaminating MV in the EV preparation. To confirm the
functionality of this assay, we tested B126, an anti-B5 mAb with
IgG2a isotype previously shown to neutralize EV in the presence
of C’ [43], as well as VMC-30, an anti-B5 mAb from a previously
Antibody to Vaccinia EV, Complement, Fc Receptors
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B126 was capable of neutralizing 97% of .10
4 EV particles in the
presence of C’; however, VMC-30 was not. Neutralization was
abrogated if C’ was first heat inactivated.
Using this luciferase-based high EV particle neutralization
assay, we found that anti-A33 and anti-B5 sera from mice
vaccinated with protein and CpG/alum could neutralize large
numbers of EV particles in the presence of C’ (Fig. 3). Neu-
tralization was largely abrogated if C’ was first heat inactivated.
Anti-B5 sera was better at C’-mediated neutralization than anti-
A33 sera, though this might be explained by the higher titer of
IgG2a anti-B5 antibody compared to anti-A33 antibody (Fig. 1).
Interestingly, while anti-A33 antibodies have the ability to neu-
tralize EV in the presence of C’, there was a lack of protection in
mice vaccinated with A33/CpG/alum.
Anti-A33 C’-mediated antibody neutralization requires steps
that could lead to EV outer envelope lysis, while anti-B5
C’-mediated antibody neutralization can occur by
opsonization
To elucidate why the A33/CpG/alum vaccination was not as
effective as B5/CpG/alum at protecting mice from lethal
challenge despite neutralizing EV in the presence of C’, we asked
Table 1. Summary of survival and maximum weight loss after challenge with 4610
6 pfu VACV.
Vaccination group
a Percent survival
Maximum percent average weight
loss
b
ABL/CpG/alum 100 10
AL/CpG/alum 100 2
BL/CpG/alum 100 12
L1/CpG/alum 80 23
B5/CpG/alum 40 24
A33/CpG/alum 0 N/A
ABL/alum 0 N/A
AL/alum 0 N/A
BL/alum 0 N/A
L1/alum 0 N/A
B5/alum 0 N/A
A33/alum 0 N/A
unvaccinated 0 N/A
a. A, B, L: A33, B5, L1, respectively. Alum: aluminum hydroxide.
b. N/A: not applicable. Since these groups had 0% survival, average weight loss of the group is not reported since mice were sacrificed when they had 30% weight loss
or died prior to reaching this degree of weight loss.
doi:10.1371/journal.pone.0020597.t001
Figure 1. Antibody isotypes produced in BALB/c mice after
vaccination. Groups of 6-week old female BALB/c mice (9 mice/group)
vaccinated individually with A33, B5, or L1 adjuvanted with alum +/2
CpG were bled three weeks after the boost vaccination. Equal volumes
of heat-inactivated serum from individual mice in each group were
pooled. Shown are reciprocal end-point dilutions for antibody isotypes
IgG1 (white bars) and IgG2a (black bars) as measured by ELISA reactivity
with proteins A33, B5, or L1. Vaccinations without CpG produced no
detectable IgG2a response.
doi:10.1371/journal.pone.0020597.g001
Figure 2. Neutralization of large numbers of EV particles using
anti-B5 mAbs and complement. Anti-B5 mAb B126 (squares) and
anti-B5 mAb VMC-30 (circles) were used in a luciferase-based high PFU
EV neutralization assay. ,5610
4 pfu of EV was incubated with
increasing concentrations of mAb in the presence of 10% baby rabbit
C’ (solid symbols) or heat inactivated baby rabbit C’ (iC’) (open symbols).
Luciferase units were converted to PFU by linear regression of a
standard curve using known numbers of EV. Neutralization was
performed in triplicate for C’ and duplicate for iC’ and represents two
independent experiments. Error bars represent standard deviation.
doi:10.1371/journal.pone.0020597.g002
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role. Lustig, et al. demonstrated that anti-A33 polyclonal rabbit
sera (pAb) resulted in C’-mediated lysis of the outer membrane of
EV allowing anti-MV neutralizing antibody access to the MV
particle within [31]. Benhnia et al. showed that anti-B5 mouse
mAb B126 neutralized EV by opsonizing particles with comple-
ment and could neutralize in the absence of membrane attack
complex formation and without an anti-MV antibody present
[43]. However, the question remained whether these observations
with anti-A33 and anti-B5 antibodies were due to the differing EV
target proteins or if the differences in C’-mediated neutralization
was due to inherent differences in the two studies (e.g., pAb vs.
mAb, rabbit vs. mouse antibodies, and different adjuvants used
during generation of the antibodies). To determine if different C’-
mediated neutralization pathways might be used for different EV
protein targets, sera from mice vaccinated with either A33 or B5 /
CpG/alum were used with human C’ depleted for C5 or C1q
(Figs. 4A–C). Depletion of either C1q or C5 from sera significantly
reduced the ability of anti-A33 mouse sera to efficiently neutralize
EV (Fig. 4A) indicating that steps that lead to formation of the
membrane attack complex were required for neutralization.
However, only the sera depleted of C1q affected the ability of
anti-B5 mouse sera to neutralize EV (Fig. 4B) indicating that
membrane attack complex does not need to form for successful EV
neutralization. Similar results were obtained when rabbit pAb
against A33 and B5 was used (Figs. 4D and E). These results are
consistent with the previously described findings that the mecha-
nism of C’-mediated neutralization for A33 and B5 differ[31,43],
with anti-A33 antibody relying on virolysis and anti-B5 antibody
able to neutralize by opsonization (Figs. 4C and F).
Benhnia hypothesized that antibody alone was unable to fulfill
the basic occupancy model for EV neutralization because of the
amount of B5 protein on the EV surface and that antibody-
induced C’ coating of the EV membrane allowed for the occu-
pancy model to succeed [42]. To examine this further, we varied
the anti-B5 antibody concentration as well as used EV that in-
corporated different C’ regulators into its outer envelope. These C’
regulators (CD55 and CD59) have been shown to be present on
the EV envelope [49]. CD55, also known as decay-accelerating
factor, inhibits stable formation of the C3 convertase and down-
modulates the amount of C3b/C4b deposition as well as the
downstream steps in the C’ cascade [56] and thus could alter the
ability of C’ to opsonize EV. CD59, or protectin, prevents for-
mation of the membrane attack complex and could block virolysis
of the EV membrane. We produced EV that had each C’
regulator on its surface using previously described SVAREC cell
lines that expressed no human C’ regulators or were stably
transfected to express human CD55 or CD59[49,50]. At high
concentrations of anti-B5 sera (1:80), EV produced in the cell line
expressing CD55 showed some protection from C’-mediated
neutralization (Fig. 5, striped bar), while EV produced in the cell
line expressing CD59 showed no protection from C’-mediated
neutralization (Fig. 5, white bar). This data supports a model
where virolysis is not needed since the presence of CD59 did not
alter the ability to neutralize EV at the relatively high con-
centration of antibody. However, at relatively low concentrations
of anti-B5 sera (1:640), EV produced in the cell lines expressing
CD55 or CD59 were equally protected from C’-mediated
neutralization (striped and white bars). The finding that CD59
provides protection equal to that of CD55 when antibody is at low
concentration indicates that virolysis becomes the predominant
pathway for neutralization. Therefore, if the amount of antibody
on the surface of EV is limited, virolysis is required for neu-
tralization as was seen with anti-A33 sera.
Complement is partially responsible for the protection
seen in mice after passive or active immunization
To determine what effector functions of antibody were impor-
tant for in vivo protection, we used immunizations that targeted B5.
Benhnia et al. found that passive immunization with mAb B126
was less protective in vivo if mice were first transiently depleted of
C’ using cobra venom factor (CVF) [43]. However, mice still
recovered and were more protected than naı ¨ve mice. To first
confirm the contribution of C’ in protection by a polyclonal anti-B5
antibody response, we passively transferred pAb rabbit anti-B5
antibody (R182) into C3 knockout (C3KO) and wild-type mice
(C57BL/6) and intranasally (i.n.) challenged them with a lethal dose
of VACV (Fig. 6). C3KO mice lost significantly more weight than
C57BL/6 mice indicating that C’ contributed to protection. How-
ever, similar to Benhnia et al. [43], when compared to the controls
that were not treated with antibody, we did note partial protection
in the absence of C’. Next, to determine if antibodies produced
during active immunization protected in a similar fashion, we
vaccinated C3KO and wild-type C57BL/6 mice with B5/CpG/
alum. Interestingly, despite a few reports that C3KO mice were
Figure 3. Neutralization of large numbers of EV particles using
sera from mice vaccinated with A33 or B5 in CpG/alum or alum
only. Sera from BALB/c mice vaccinated with A33 (A) or B5 (B)
adjuvanted with CpG/alum (squares) or alum only (circles) were
collected 3 weeks post boost vaccination. Equal volumes of heat-
inactivated serum from groups of mice were pooled (9 mice/group).
,5610
4 pfu of EV was neutralized with increasing amounts of sera in
the presence of 10% baby rabbit C’ (closed symbols) or heat inactivated
baby rabbit C’ (iC’) (open symbols). Luciferase units were converted to
PFU by linear regression of a standard curve using known numbers of
EV. Neutralization was performed in triplicate for C’ and duplicate for iC’
and represents three independent experiments. Error bars represent
standard deviation.
doi:10.1371/journal.pone.0020597.g003
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our vaccine resulted in total IgG and IgG2c responses comparable
to the wild type C57BL/6 mice (Fig. 7A). After vaccinations, mice
were challenged i.n. with VACV and weight loss was monitored.
Vaccinated C57BL/6 mice lost minimal weight and fully recovered
by day 8 post-infection. Conversely, vaccinated C3KO mice lost
significant weight similar to C57BL/6 naı ¨ve and C3KO naı ¨ve mice
(Fig. 7B) again indicating a role of C’ in protection from challenge.
Figure 4. Contribution of steps leading to the formation of the membrane attack complex in complement-mediated neutralization
of EV. Graphed is the percent neutralization of EV in the presence of antibody and 20% human C’ or with human C’ depleted of component C5 or
C1q. Sera from BALB/c mice vaccinated with A33 or B5/CpG/alum was used at a dilution of 1:20 (A–C). Rabbit pAb against A33 and B5 was used at
50 mg/mL (D–F). Data shown in A, B, D, and E are percent neutralization of no antibody control. Data in C and F show the specific EV neutralization
dependent on C5 (virolysis) and was calculated as described in materials and methods. Neutralizations were performed in triplicate. Error bars
represent standard deviation. * p,0.05.
doi:10.1371/journal.pone.0020597.g004
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B5 antibody in the absence of complement
In the work by Benhnia, et al [43], it was unclear whether the
recovery of normal levels of C’ after CVF depletion or effector
functions mediated through Fc receptors (FcRs) were responsible
for the protection afforded by mAb B126 even after C’ depletion.
Based on our findings in C3KO mice, it was evident that ad-
ditional mechanisms were playing a role in protecting mice in the
absence of C’. Thus, we passively transferred FcRKO mice with
anti-B5 pAb (R182) and i.n. challenged them with a lethal dose of
VACV (Fig. 8). These mice lost significant weight (,25%) but all
survived challenge. However, if FcRKO mice were transiently
depleted of C’ with CVF before challenge, all mice succumbed to
infection indicating that both FcR and C’ play a role in protection
(Fig. 8B). Given the finding that FcRs play a role in protection with
rabbit polyclonal anti-B5 antibody, we sought to determine if mAb
B126 also used FcRs to protect mice from lethal challenge. B126
was passively transferred into FcRKO or wild type BALB/c mice
followed by i.n. challenge with a lethal dose of VACV (Fig. 9). By
day 6, significant differences were seen in the weight loss of these
BALB/c and FcRKO mice treated with B126. By day 8, B126
treated FcRKO mice had succumbed to infection while the wild
type BALB/c mice that received B126 had already started to
recover and ultimately survived challenge again indicating an
important role for FcR in protection after passive immunization.
Discussion
Vaccine induced antibodies have been shown to be critical for
protection from orthopoxvirus challenge [14,60–62]. Likewise,
protection afforded by protein vaccination is thought to heavily
depend on antibody responses generated and often these
responses are measured and reported as a possible correlate of
protection [15,23,28,30,32–34]. However, besides direct patho-
gen neutralization, these antibody responses could protect
through various effector mechanisms such as activation of C’ to
neutralize virus or lyse infected cells and activating cellular
responses through FcRs to lyse and kill infected cells. Here, we
examined the functionality of antibody responses generated after
vaccination with individual VACV proteins to better understand
the type of antibody response needed to confer protection.
Recently, Benhnia et al. showed that a mouse anti-B5 mAb
named B126 required C’ to neutralize VACV EV and mediate in
vivo protection [43]. Therefore, we examined whether the same
was true for pAb responses after active or passive immunization
against the VACV EV protein B5.
To do this, we initially set up a new luciferase based assay to
measure the neutralization of large numbers of EV particles. B126
was confirmed to neutralize EV in the presence of C’ (Fig. 2) as
had been previously reported [43]. We also tested another anti-B5
mAb (VMC-30; [55]) and found that it was unable to neutralize
EV in the presence of C’ (Fig. 2). Benhenia et al, reported that
B126 was an IgG2a isotype and this afforded it the ability to
activate C’ as mAbs of IgG1 isotype did not [43]. Interestingly,
VMC-30 is an IgG2b isotype [55], which should also be capable
of activating C’ and other effector functions similar to IgG2a
[63–66]. However, in this case, the isotype of the mAb did not
predict functional activity in vitro and therefore highlights the
importance of testing functional activity of mAb and not relying
solely on the prediction of isotype analysis. When passively
transferred into mice, VMC-30 also did not protect against
challenge (data not shown), again demonstrating the need for
effector function for protection in vivo. We confirmed the isotype of
VMC-30 and speculate that it may have been unable to neutralize
VACV in the presence of C’ due to potential amino acid changes in
the Fc region of the mAb which could abrogate functional activity
[67,68]. However the IgG2b isotype could interact with Fc
receptors, so other factors like affinity may be playing a role in its
inability to protect. The role of IgG2b in mediating protection from
vaccinia virus infections in vivo is currently unknown. This may be
interesting to examine further in the future.
Figure 5. Protection of EV by human regulators of complement
from complement-mediated neutralization at high and low
amounts of antibody. Sera from BALB/c mice vaccinated with B5/
CpG/alum was used to neutralize EV produced in SVAREC cells
expressing CD55 (striped bars), CD59 (white bars), or no human
regulators of C’ (black bars) in the presence of 20% human C’. While a
full range of antibody dilutions were tested, shown is a representative
low dilution (1/80) and high dilution (1/640) of antibody and the effect
on complement-mediated neutralization of EV containing CD55 or
CD59. The full range of antibody dilutions revealed that EV was partially
protected by CD59 at dilutions between 1/80 and 1/640, but not as
protective as CD55 at those dilutions. Data is shown as percent
neutralization of no antibody control. Error bars represent standard
deviation. * p,0.05.
doi:10.1371/journal.pone.0020597.g005
Figure 6. Protection from vaccinia virus challenge by anti-B5
rabbit pAb in C57BL/6 and C3KO mice. Anti-B5 rabbit pAb (R182; 2
mg/mouse) were passively transferred by the i.p. route into 9-week old
female C57BL/6 (circles) and C3KO (squares) mice. Groups of mice that
did not receive antibody treatment were included (dashed lines and
open symbols). Twenty-four hours after antibody treatment, mice were
i.n. challenged with ,9610
4 pfu of vaccinia virus. Weight loss was
monitored and the percent weight loss calculated against each mouse’s
starting weight. Five of 5 mice in each R182 treated group survived
challenge while 4 of 4 naı ¨ve C57BL/6 and 3 of 4 naı ¨ve C3KO mice did
not. Error bars represent standard error. * p,0.05.
doi:10.1371/journal.pone.0020597.g006
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served that protection in vivo by protein vaccination was cor-
related with the production of IgG2a antibodies (Table 1 and
Fig. 1). Therefore, we predicted that these antibodies would
neutralize EV in the presence of C’ similar to B126, but we needed
to fully examine this given the lack of C’-fixing activity with mAb
VMC-30. We found that sera containing IgG2a from mice
vaccinated with A33 or B5/CpG/alum could utilize C’ to neu-
tralize large numbers of EV particles in vitro. Sera lacking IgG2a
antibody from mice vaccinated with proteins and alum only was
unable to neutralize virus in the presence of C’ (Fig. 3). This
confirms the importance of isotype and strengthens the correlation
between protection of mice and production of IgG2a isotype
antibodies.
Further examination of the mechanism of C’-mediated neu-
tralization revealed that anti-A33 and anti-B5 antibody responses
utilized C’ to neutralize EV in different ways (Fig. 4). In agreement
with previous reports [31,42,43], A33 antibody required C’
activation steps that could lead to virolysis, while B5 antibody
and C’ could neutralize through opsonization. Benhnia et al.
provided a model of anti-B5 antibody- C’ mediated neutralization
whereby B5 protein was not in high enough density on the surface
of EV to allow for the basic occupancy model of antibody neu-
tralization to succeed [42,43]. They reasoned that deposited C’
components enhanced the footprint of antibody bound to B5
protein on the virus surface to assist in neutralization. This model
explained why virolysis was not needed. Lustig et al. provided a
model of C’ assisted EV neutralization for anti-A33 antibody [31].
In this model, C’ lyses the outer envelope of EV, which provides
anti-MV antibody access to the MV virion within. An anti-MV
antibody was required to be present during the assay for C’
assisted neutralization to occur. Because our luciferase based EV
neutralization assay always contains an anti-MV antibody to
eliminate contaminating MV in the EV preparations, we were
unable to examine neutralization in the absence of an anti-MV
antibody. Despite this, our data suggests that both mechanisms are
correct for each protein target and not due to differences in anti-
body species, clonality, or adjuvant used to generate the antibody.
We hypothesized that disparity in A33 and B5 protein density
on the EV surface contributed to the difference in mechanism.
Galmiche et al. showed that total EV lysate had A33 and B5
protein amounts of ,5 mg/mg and 30 mg/mg, respectively [15].
The reduced amount of A33 protein on the EV surface could
decrease the amount of antibody bound to EV to the point where
coating with C1q and C3b/C4b in the area around the bound
antibody is still insufficient to completely opsonize the EV virion.
Under this scenario, formation of even one or two membrane
attack complexes (MAC) on the EV virion could be enough to
disrupt the outer membrane and allow access of neutralizing MV
antibody. This model would predict that further limiting the
amount of anti-B5 antibody bound to the EV surface (equivalent
to a lower density of protein) would switch the mechanism of C’-
mediated neutralization from opsonization to lysis. To test this
hypothesis, we used a novel approach whereby EV was generated
with the incorporation of different human regulators of C’ (Fig. 5).
We found that when EV was generated in cells that would result in
the inclusion of CD59 (an inhibitor of MAC formation) on EV,
CD59 could not provide additional protection from C’-mediated
neutralization at high concentrations of anti-B5 antibody as
neutralization could occur through opsonization. However, at low
concentrations of anti-B5 antibody, CD59 was protective against
C’-mediated neutralization to the same degree as EV containing
Figure 7. Protection from vaccinia virus challenge by B5/CpG/alum vaccination in C57BL/6 and C3KO mice. 9-week old male C57BL/6
(circles) (5/group) and C3KO (squares) (6/group) mice were vaccinated with B5/CpG/alum. (A) Anti-B5 total IgG and IgG2c were measured by ELISA
from sera taken from vaccinated mice 3 weeks after boost vaccination. Because C57BL/6 mice do not have the gene for IgG2a, IgG2c was measured
and is known to have similar effector functions [58,74,75]. (B) Three weeks after the boost vaccination, mice were i.n. challenged with ,2610
5 pfu of
vaccinia virus. Unvaccinated naı ¨ve C57BL/6 and C3KO groups were included (3 mice/group) (dashed lines and open symbols). Weight loss was
monitored and the percent weight loss calculated against each mouse’s starting weight. One of the B5/CpG/alum vaccinated C57BL/6 mice lost
significantly more weight than the other 4 mice in its group and was removed from analysis based on Grubbs’ test for outlier detection. Error bars
represent standard error. Data shown is representative of two independent experiments. * p,0.05. At time of challenge, the mice were ,14 weeks
old and at this challenge dose in the C57BL/6 background only about half of the unvaccinated mice required euthanasia. Thus, mortality between
groups was not statistically significant.
doi:10.1371/journal.pone.0020597.g007
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the mechanistic switch from opsonization to lysis. Additionally, we
found that under the right experimental conditions, human reg-
ulators of C’ on the VACV EV surface can block C’ activation by
antibody, and not just activation by C’ alone [49]. These findings
provide new insight into interactions of antibody, C’, and viral
protein and how those interactions impact neutralization of virus.
The finding that A33 requires virolysis for C’-mediated neu-
tralization while B5 does not may also explain differences in
protection we observed after vaccinating with A33 or B5/CpG/
alum. At the challenge doses we used, the ability of B5 to provide
at least partial protection could be explained by the ability to
neutralize EV in the absence of an anti-MV antibody response,
which A33 is incapable. A33 antibody and C’ would simply release
MV particles which could propagate the infection, albeit that some
anti-A33 effect could be gained by allowing C’ free access to the C’
sensitive MV particle or A33 antibody-dependent lysis of infected
cells. This may also explain why a vaccine that adds L1 to A33
improves protection from disease compared to A33 or L1 alone
(Table 1).
To examine more closely which effector functions of antibodies
are important for protection in vivo, we studied the role of C’ and
FcRs in the protection we observed with B5 antibody. The rabbit
anti-B5 pAb used in neutralization experiments had been
previously shown to be protective in vivo by passive immunization
[26] and the ability to neutralize EV in the presence of C’
potentially contributed to this observation. To confirm this, we
examined the ability of anti-B5 antibody to protect mice in the
absence of the central C’ component C3 (Figs. 6 and 7). We found
that both passive immunization with rabbit anti-B5 antibody and
active immunization with B5/CpG/alum partially relied on C’ for
protection. Similar to previously reported studies that transiently
depleted C’ in challenged animals [43,69], we found that antibody
could still provide partial protection even in the genetic absence of
C3, which abrogates the function of the C’ system (Figs. 6 and 7B).
Somewhat unexpectedly, we found that vaccinated C3KO mice
generated antibody responses similar to that of wild-type mice
(Fig. 7A). Binding of the B cell antigen receptor/co-receptor by
C3d-antigen complexes lowers the threshold for B cell activation
by 10- to 100-fold [70] and provides an important survival signal
to B cells [71]. CpG has been shown to directly stimulate B cells
and enhance IgG secretion [72,73]. Inclusion of CpG in our vac-
cine may stimulate B-cells in a way that overcomes the require-
ment of C’ activation for B-cell priming, activation, and survival.
Because we observed partial protection in the absence of C’, we
examined whether FcRs may be playing a role in protection as was
previously suggested by Benhnia et al. [43]. FcRKO mice were
partially protected by passive transfer of rabbit anti-B5 pAB, but
not if C’ was transiently depleted with CVF first (Fig. 8). Likewise,
anti-B5 mAb B126 was heavily reliant on FcRs for its protective
effects (Fig. 9). This finding indicates that both C’ and FcRs can
contribute to protection and that both are important effector fun-
ctions that mediate protection by pAb anti-B5 responses in vivo.
In summary, we found that after active vaccination, pAb
responses against the EV form of VACV utilize C’ and FcRs to
mediate protection. C’ plays an important role in neutralization
and the protein target can alter the mechanism through which this
neutralization occurs. FcRs contribute to protection in vivo likely
through Fc mediated phagocytosis and/or ADCC. Together these
effector functions cooperate to provide protection from challenge.
Figure 8. Protection from vaccinia virus challenge by anti-B5
rabbit pAb in FcRKO mice. Anti-B5 rabbit pAb (R182; 2 mg/mouse)
were passively transferred by the i.p. route into 7- to 13-week old
female FcRKO mice (8 mice/group; circles). Approximately 4 units of
cobra venom factor were delivered on days 21, 2, and 5 by the i.p.
route to one group of mice that received R182 (open circles). A group
FcRKO mice that did not receive antibody or CVF was included (crosses).
Twenty-four hours after antibody treatment, mice were i.n. challenged
with ,3610
5 pfu of vaccinia virus. (A) Survival differences between the
FcRKO mice treated with R182 and those treated with R182 and CVF
were statistically significant; p=0.0084 (Log-rank Test). (B) Weight loss
was monitored and percent weight loss calculated against each
mouse’s starting weight. Error bars represent standard error. Data
shown is representative of two independent experiments.
doi:10.1371/journal.pone.0020597.g008
Figure 9. Protection from vaccinia virus challenge by anti-B5
mAb B126 is FcR dependent. Anti-B5 mAb (B126; 100 mg) was
passively transferred by the i.p. route into 8- to 9-week old female
FcRKO (closed circle) and 8-week old female BALB/c mice (closed
squares) (4 mice/group). A naı ¨ve female BALB/c control group was
included (dashed line, open square). Twenty-four hours after antibody
treatment, mice were i.n. challenged with ,4610
5 pfu of vaccinia virus.
Weight loss was monitored and percent weight loss calculated against
each mouse’s starting weight. Error bars represent standard error. Data
shown is representative of two independent experiments. * p,0.05. All
BALB/c mice given B126 survived challenge, while FcRKO mice given
B126 and untreated BALB/c mice all succumbed to infection and/or
reached end-point criteria for euthanasia.
doi:10.1371/journal.pone.0020597.g009
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function requirements for protection in vivo to any pathogen,
especially if monoclonal antibodies are to be used. Advances in the
understanding of the molecular basis for effector functions of anti-
body allows for customization. By altering the Fc region amino
acid sequence one can impart or abrogate specific effector fun-
ctions [67]. By understanding the mechanism by which antibodies
provide protection against a given pathogen and understanding
how to manipulate antibody effector functions, vaccines and other
therapeutic antibodies can be designed to specifications that acti-
vate C’ or FcRs as necessary.
Supporting Information
Figure S1 Cobra Venom Factor (CVF) treatment of
BALB/c mice transiently depletes complement. To assess
the degree of C’ depletion after CVF treatment, groups of 11- to
12-week old female BALB/c mice (2 mice per group) were treated
with CVF and then terminally bled the following day. One group
was treated on day -1 and bled the next day (d0). A second group
was treated on days -1 and +2 and bled the next day (d3), A third
group was treated on days 21, +2, and +5 and bled the next day
(d6). A group of untreated mice was used a control (No CVF). (A)
CH50 assay using rabbit erythrocytes (Complement Technology,
Tyler, TX) sensitized with goat anti-rabbit erythrocyte antibody
(MP Biomedicals, Solon, OH) was performed with sera from mice
treated or not treated with CVF. Complement activity levels on
days 0 and 3 were low, while some complement activity returned
by day 6. Note that sensitized rabbit erythrocytes were used
because sensitized sheep erythrocytes are resistant to lysis by
mouse complement. (B) Western blot of C3 protein in sera of mice
treated or not treated with CVF. Serum (2 ml) from the indicated
group of mice was loaded on to a 10% polyacrylamide gel. After
blotting, HRP-conjugated goat anti-mouse C3 antibody (MP
Biomedicals, Solon, OH) at 1:10,000 was used to probe for the
presence of C3. C3 protein was not detected on days 0 and 3,
while some C3 protein was detected on day 6.
(TIF)
Figure S2 CD55 and CD59 are detected in stably
transfected SVAREC cell lines. SVAREC cell lines stably
transfected to express CD55 and CD59 [49,50] were grown under
selective pressure as described in materials and methods. Western
blotting for either CD55 (aCD55) or CD59 (aCD55) was
performed on lysates from the parental SVAREC cell line
expressing no human complement regulators (Par), a SVAREC
cell line expressing CD55 (CD55), and a SVAREC cell line
expressing CD59 (CD59). Rabbit polyclonal anti-human CD55
and anti-human CD59 antibodies were used at a dilution of 1:250.
CD55 was only detected in the CD55-expressing cell line at its
expected size of ,70 kDa and CD59 was only detected in the
CD59-expressing cell line at its expected size of ,20 kDa.
(TIF)
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